Briefing: White House Works to Win Pharma Support for Drug Pricing Bill
Strategic angle: The White House is working to build support for drug pricing legislation, part of an election year focus on affordability.
Briefing: From engineered fungal molecules to drug leads, chem-bio hybrid synthesis enables antiparasitic drug discovery
Strategic angle: Amebiasis, caused by Entamoeba histolytica, affects millions globally, highlighting the need for innovative drug discovery methods.
FDA Approves Denali Therapeutics Drug for Hunter Syndrome
A significant decision by the FDA following previous rejections of rare disease treatments.
Briefing: Heart failure is common. A quick MRI could improve diagnosis and guide treatment
Strategic angle: A new MRI method measures cardiac oxygen use in three minutes without catheters or radiation, offering a simpler way to study heart failure and metabolism.
Briefing: Federal vaccine adviser departs ACIP
Strategic angle: Robert Malone, an outspoken doctor and ally of RFK Jr., is stepping away from a panel of federal vaccine advisers after a federal judge blocked the panel’s work.
Briefing: Pharmalittle: Trump Drug Pricing Flaw and Gilead Deal Insights
Strategic angle: Comments from a top Trump administration health official highlight significant issues in the president’s drug pricing plans.
Briefing: New lipid nanoparticle design improves precision of mRNA vaccine delivery
Strategic angle: Penn Engineers have redesigned a key component of lipid nanoparticles to enhance targeting and reduce off-target effects.
Briefing: The potential loophole in Trump’s plan to get other countries to pay more for drugs
Strategic angle: Diverging messages on the main effort to address U.S. drug prices point to a loophole in Trump's plan.
Iran war has not disrupted pharma supply chains. That could change if conflict is prolonged
The escalating war in the Middle East so far has not appreciably disrupted global pharmaceutical supply chains, but it could eventually — affecting prices.
Briefing: Pfizer’s Lyme Vaccine Results Set Up Tricky Regulatory Path
Strategic angle: New results on Pfizer's Lyme disease vaccine raise questions about its regulatory approval.
Briefing: Pfizer’s Lyme vaccine shows efficacy, but misses key statistical hurdle
Strategic angle: A new vaccine shows some promise in combating Lyme disease, which affects nearly half a million Americans annually.
Briefing: India news: New Delhi sends medical aid to Afghanistan
Strategic angle: India has dispatched 2.5 tons of emergency medical supplies to Kabul following a recent airstrike.
Briefing: 'Drug transactions' allegedly on Holloway's phone
Strategic angle: Prosecutors allege drug transactions were found on Crimson Tide basketball star Aden Holloway's phone after his arrest on a felony drug charge.
US prosecutors investigate Colombia’s Petro over suspected ties to drug traffickers
Colombian President Gustavo Petro is under scrutiny by US federal prosecutors for alleged connections to drug trafficking.
Briefing: ACIP Conflict Tests Trump's Support for RFK Jr.'s Vaccine Policy Overhaul
Strategic angle: The Trump administration faces a pivotal decision on vaccine policymaking following a court ruling, with potential political ramifications.
Briefing: Drug development is booming in China. Should the U.S. view it as a threat or an opportunity?
Strategic angle: If the U.S. wants to hold on to its title as the world's top biotech innovator, it might want to take a page out of China's book.
Briefing: Trump’s Medicare Director Seeks to Rein in Expectations for TrumpRx
Strategic angle: The Trump administration is counting on its drug pricing efforts to help with the midterm elections.
Novo Nordisk’s high-dose Wegovy approved in the U.S.
A high-dose version of Novo Nordisk’s injectable obesity drug Wegovy received U.S. approval.
Two doctors on the challenges of medicine today
In today's Morning Rounds newsletter, a Texas couple getting rich off out-of-network medical bills, two doctors on the challenges of medicine today, and more.
Briefing: Will the Jalisco cartel's new US-born leader complicate Trump's war on drugs?
Strategic angle: An analysis of the implications of the Jalisco cartel's leadership change on US drug policy.